The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib.
J. M. Lafky
No relevant relationships to disclose
B. M. Bot
No relevant relationships to disclose
B. W. Morlan
No relevant relationships to disclose
S. K. Anderson
No relevant relationships to disclose
T. K. Kimlinger
No relevant relationships to disclose
T. M. Halling
No relevant relationships to disclose
S. Kumar
Consultant or Advisory Role - Merck (U)
Honoraria - Merck
Research Funding - Celgene; Genzyme; Millennium; Novartis
J. T. Reynolds
No relevant relationships to disclose
P. J. Stella
No relevant relationships to disclose
S. R. Dakhil
No relevant relationships to disclose
W. S. Loui
No relevant relationships to disclose
S. R. Alberts
Consultant or Advisory Role - Bayer (U); Bristol-Myers Squibb (U)
Research Funding - Bayer; Bristol-Myers Squibb
A. Grothey
Consultant or Advisory Role - Bayer (U); Roche/Genentech (U)
Research Funding - Bayer; Roche/Genentech